Anupam Rasayan India Ltd Q2 FY26 — “From Pesticides to Polymers: India’s Favourite Lab Experiment on Debt and Dreams”
1. At a Glance
Anupam Rasayan India Ltd ( NSE: ANURAS ) just pulled off a quarter that felt like it was sponsored by caffeine and contracts. Q2 FY26 revenue came in at ₹ 739 Cr (+149 % YoY!) and PAT ₹ 57 Cr (+166 % YoY!) — basically the chemical version of a Red Bull ad.
At ₹ 1,065 a share and a market cap ₹ 12,121 Cr, the stock trades at 80 × earnings, because apparently optimism is a solvent now. ROE 3.3 %, ROCE 7.3 %, Debt ₹ 1,223 Cr (D/E 0.38 ×), Book Value ₹ 281, and Dividend Yield 0.07 %. Promoter holding 59.1 % ( down 2 pp QoQ ) — someone clearly sold a few molecules for cash.
Operating margin 25 %. Order book ₹ 8,900 Cr. Six plants in Gujarat churning out 27,000 MT of chemicals and one very ambitious storyline.
2. Introduction
When chemistry students dream big, they usually land in a lab. Anupam Rasayan landed on Dalal Street.
Founded in 1984, the company specializes in life-science and other specialty chemicals — serving everything from crop protection to lip protection. Its clients read like a science Olympiad sponsor list — Syngenta, Adama, Sumitomo, DuPont, and Nissei. Top 10 clients = 77 % of revenues, which is comforting until one client sneezes.
The company’s order book is bigger than its balance sheet ( ₹ 8,900 Cr vs ₹ 5,650 Cr assets ). That’s ambition, not arithmetic. They’ve signed LOIs worth hundreds of millions with Japanese and Korean firms for battery solvents and fluorine chemicals — because every Indian manufacturer now wants to be part of the EV fairy tale.
But beneath the glow of solar plants and press releases, ROE is barely 3 %. The balance sheet glows brighter than the profit sheet.
3. Business Model – WTF Do They Even Do?
In one line: They mix expensive molecules for other people’s patents and make it sound like alchemy.
Life Science Specialty Chemicals ( 91 % of FY24 revenue )
Agrochemicals (65 %) – Intermediates and actives for pesticides, herbicides, fungicides.
Personal Care (17 %) – UV filters and antibacterials for brands that claim to “protect you from germs and judgment.”
Pharma (9 %) – Key starting materials for APIs — the Netflix prequels of pharma.
India 36 %, Europe 30 %, Japan 16 %, Singapore 11 %, Others 7 %. If chemistry were cricket, Japan is the surprise all-rounder.
Clients take 12–24 months to onboard — so it’s less “customer acquisition” and more “arranged marriage after background check.”
4. Financial Overview
Source table
Metric (₹ Cr)
Q2 FY26
Q2 FY25
Q1 FY26
YoY %
QoQ %
Revenue
739
296
486
+149 %
+52 %
EBITDA
143
79
124
+81 %
+15 %
PAT
57
21
48
+166 %
+19 %
EPS (₹)
3.9
1.5
3.1
+160 %
+26 %
Commentary: The YoY jump looks spectacular, but remember FY25 was the chemical hangover year when realizations fell and inventories rose. Margins are recovering as new plants and contracts kick in. EBITDA margin 19 % vs 27 % last year still below pre-Capex norms.
